AQP Bespoke Workshops
Live, high-impact workshops that build AQP judgement, tighten ABPI decision-making, and reduce rework—built around your real materials and real scenarios.
ABPI-first thinking for high-risk decisions (claims, meetings, digital, public)
“What good looks like” standards + defensible rationale
Live critique of your examples (slides, job bags, meeting plans)
Practical templates/checklists your team can reuse
Delivered by an ABPI Final Medical Signatory
Running a busy approval cycle? We can deliver this in a half-day or full-day format.
What you’ll achieve in a workshop
Stop debating opinions. Align your team on defensible ABPI standards and reduce approval friction immediately.
- Faster, more consistent AQP decisions across Marketing/Medical/Compliance
- Stronger claims with clearer evidence logic and balanced framing
- Reduced PMCPA risk in high-pressure scenarios (meetings, congress, digital)
- A reusable “decision kit”: checklists, wording patterns, and sign-off principles
Bespoke Workshops (choose your topic)
Pick one area for a sharp half-day session, or combine themes for a full-day workshop
Meetings approval (incl. international congresses)
Advisory Boards
Press releases & external comms
Claims & substantiation
Digital & social media
High-risk “edge cases” & escalation drills
How it works
A workshop built around your real needs - delivered live.
Each session is tailored to your portfolio, your materials, and your internal process—so the learning lands immediately in day-to-day approvals.
Pre-work: we tailor the session to your needs
Before the workshop, we agree your objectives and review a small set of examples (e.g., claims, slides, meeting plans, digital copy). This lets us pinpoint your recurring risk patterns and focus the workshop on what will actually matters to you. • Select 3–6 real examples (sanitised if needed) • Agree “rules of thumb” your team will use • Build a session plan around your highest-risk activities
Live workshop + practical decision toolkit
The workshop mixes teaching, live critique, and scenario drills. We pressure-test wording, substantiation, balance, and meeting governance—then convert it into a repeatable toolkit your team can use immediately.
FAQ
Frequently Asked Questions
The workshop is a fast, live intervention—ideal for aligning teams quickly and fixing recurring risk patterns. The mentorship programme is deeper and longer-term, building judgement over time with weekly modules, case learning, and coaching.
Yes. We tailor examples, scenarios, and decision frameworks to your portfolio, claims style, approval process, and internal standards—so the output is usable immediately.
Yes. We typically use a small set of sanitised real examples (slides, job bags, meeting plans, digital copy) to make the learning practical and directly relevant.
Common themes include: claims and substantiation, balance and context, meetings/congress governance, digital/social risk, materials for the public, grants/donations, and building a consistent AQP decision approach.
AQPs, scientific/medical reviewers, originators, marketing leads, compliance colleagues, and anyone involved in approvals. Mixed groups work well because alignment reduces friction.
Yes. We can add short 1:1 sessions after the workshop to provide targeted feedback on judgement, rationale writing, and escalation decisions.
Yes. You’ll receive a practical pack: checklists, decision rules, example wording patterns, and a summary of “what good looks like.”
Yes. Workshops can be delivered in-person or live online. Online sessions still work very well when participants bring real examples and we use structured drills.
Click Book a Call and we’ll confirm objectives, format, attendees, and timings. You’ll then receive a simple plan and quote.
Latest info
Latest PMCPA Cases and News
AstraZeneca: promotional meeting misclassified and LinkedIn ‘likes/reposts’ led to pre-authorisation promotion and public advertising concerns (AUTH/3729/1/23)
Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting an unlicensed medicine and a POM to the public.
Otsuka Europe: UK website product pages ruled to promote prescription-only medicines to the public
An anonymous employee complained that Otsuka UK webpages listed POM brand/generic names and indications. The Panel ruled the pages promoted POMs to the public and were not access-restricted, breaching Clauses 26.1, 26.2, 28.1 and 9.1.
Boehringer Ingelheim voluntary admission: MIMS issue carried Spiolto Respimat advertising on more than two pages
Boehringer Ingelheim admitted that June 2019 MIMS carried a Spiolto Respimat full-page ad plus a double-sided bookmark insert, exceeding the two-page limit for a single product in a print journal.
UCB employee LinkedIn profile promoted unlicensed bimekizumab (AUTH/3287/12/19)
A UCB employee’s personal LinkedIn profile described work on Phase 3 axial spondyloarthropathy for bimekizumab. The Panel ruled this promoted an unlicensed medicine and was not certified, breaching Clauses 3.1, 14.1 and 9.1.
Bristol-Myers Squibb voluntary admission: incorrect overall survival data in promotional article (Urology News)
Bristol-Myers Squibb admitted a promotional article misquoted 30‑month overall survival figures for intermediate/poor-risk aRCC by using ITT data. The online article was removed and a corrected reprint with apology was issued.
AstraZeneca voluntary admission: employee re-tweeted product-related tweets about Forxiga and Lynparza from a personal Twitter account
AstraZeneca admitted an employee re-tweeted positive clinical-trial-related posts about Forxiga and a Lynparza news tweet from a personal account. The Panel found promotion of unlicensed indications, advertising POMs to the public, and lack of certification.